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Abstract
Background: Multiple sclerosis (MS) is a complex, chronic and progressive disease and rehabilitation services can
provide important support to patients. Few MS rehabilitation programs have been shown to provide health
improvements to patients in a cost-effective manner. The objective of this study is to assess the effects in terms of
changes measured by a variety of standardized quality of life, mastery, coping, compliance and individual
goal-related endpoints. This combination provides the basis for analyzing the complexity of MS and outcomes of a
personalized rehabilitation.
Methods/Design: Patients with MS referred to hospital rehabilitation services will be randomized to either early
admission (within two months) or usual admission (after an average waiting time of eight months). They will
complete a battery of standardized health outcome instruments prior to randomization, and again six and twelve
months after randomization, and a battery of goal-related outcome measures at admission and discharge, and
again one, six and twelve months after randomization.
Discussion: The results of the study are expected to contribute to further development of MS rehabilitation
services and to discussions about the design and content of such services. The results will also provide additional
information to health authorities responsible for providing and financing rehabilitation services.
Trial registration: Current Controlled Trials (ISRCTN05245917)
Background
Multiple Sclerosis (MS) is a complex, chronic and pro-
gressive disease with currently more than 10.000 Danes
diagnosed [1]. Patient rehabilitation is necessarily also
complex, requiring a personalized, multidisciplinary and
highly specialized effort [2,3].
Modern immune drug therapy has not convincingly
delayed the progressive neurodegenerative process in
MS [4] and it remains unclear to what extent medical
treatment can prevent permanent loss of functional abi-
lities. Rehabilitation services will thus continue to be as
important as pharmacological interventions for patients
with MS. As such, they should be designed according to
guidelines based on high quality evidence and assessed
using standard evaluative methods.
Personalized rehabilitation is based on the premise that
every individual is unique in terms of biology, personality,
psychology, physical and social ability in combination with
a unique life history formed by social circumstances, daily
activities and life style. The objective of personalized
rehabilitation is to improve patients’ functional status and
to improve extroversion, activity and participation by
strengthening the individual’s motivation and ability to
cope with the disease and related challenges for living
an active life and to be active with their own rehabili-
tation. Personal rehabilitation takes place during meetings
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between active, well-prepared patients and rehabilitation
teams.
MS rehabilitation is a process that from the beginning
is matched to the patient's individual needs and desires
and includes active involvement of both the patient and
relatives. The patient has a personal coach and a trained
specialist as sparring partners throughout the rehabili-
tation process and these provide guidance to the rehabi-
litation team composed to support the patients’ needs
and goals.
Through coaching patient can be supported to set
goals for the rehabilitation. Such goals can be two-di-
mensional: to achieve at positive changes in the person's
life and to be realistic about achievable goals for the re-
habilitation process. When the goals of the rehabilitation
are determined, a unique personalized program may be
developed so that the content and intensity match the
patients’ needs, opportunities and constraints. The rehabi-
litation process can therefore be characterized as shared
decision-making between the patient (and relatives) and
the supervisor and the rehabilitation team with regular as-
sessment of content in the rehabilitation program and
progression in relation to results.
The Sclerosis Hospitals at Haslev and Ry were estab-
lished by the Multiple Sclerosis Society in 1960 to offer
specialized treatment to people with MS in Denmark.
Since the early 1990s the hospitals have had annual ope-
rating agreements with the Danish health authorities
and today are highly specialized hospitals with recent
quality accreditation from the Danish Quality Model for
Hospitals [5].
The Danish Multiple Sclerosis Hospitals provide per-
sonalized rehabilitation through a four-week inpatient
program after referral by general practitioner or neuro-
logist. A highly qualified and experienced multidiscip-
linary team collaborates with the patient in assessing
and providing a personal program based on the indi-
vidual patient’s needs. The program includes a range of
training, treatment and education focusing both on the
whole person and on specific conditions caused by MS.
The goal of the rehabilitation program is to improve
the patients' functional capacity in all relevant dimen-
sions: participation and activity; physical, social and
psychological functioning, including the patients’ ability
to cope with the disease and its symptoms and to be
active in their own rehabilitation. This personalized re-
habilitation program can be seen as a paradigm shift in
relation to an earlier and more uniform rehabilitation
program.
Evidence for MS rehabilitation
A recently updated version (April 2011) of a Cochrane
review [6] identified ten studies of varying quality and
concluded that although MS rehabilitation may have
limited effect on body functions, short-term improve-
ment in activity and participation could be observed.
Another Cochrane review suggested that exercise the-
rapy might be beneficial for muscle power function,
exercise tolerance, mobility-related activities and mood
in patients with MS, although no clear effects could
be identified in relation to fatigue or perception of
handicap [7].
The efficacy and cost-effectiveness of the Sclerosis
Hospitals rehabilitation program for MS patients were
investigated in a longitudinal study [8], in which partici-
pants completed a single outcome instrument (FAMS
questionnaire) to measure quality of life at referral, ad-
mission, discharge and up to five months after discharge.
The study showed an increase in the FAMS score from
referral and admission to discharge and thereby identi-
fied a statistically significant improvement in quality of
life. Although the FAMS scores had decreased five
months after discharge, there was still a statistically sig-
nificant improvement compared with the score at re-
ferral. The study had a number of design issues that
complicated assessment of the rehabilitation effort. As
the study had no control group, part of the observed
effect may have been due to factors other than the re-
habilitation program. The considerable variation in par-
ticipants' personal and disease-related factors could also
have influenced the observed effects.
Study objectives
The aim of the planned study is to document the effects
of a highly personalized rehabilitation program for MS
patients as provided by the Sclerosis hospitals using a
randomized controlled study design and standard gene-
ric and disease-specific outcome measures. The objective
is to assess the program’s effect on patients in terms of
changes in disease-specific quality of life and to answer
the following questions:
 To what extent are the observed effects maintained
six and twelve months after discharge?
 How do different dimensions of quality of life,
functional ability, mastery, coping, compliance and
specific measurements of sleep, daily activities, gait,
balance and activity limitations correlate?
 What individual goals are set before the start of the
rehabilitation?
 What are the central areas and priorities of the
personalized rehabilitation program?
 What specific and measurable actions are included
in the personalized rehabilitation program?
 What effect does the rehabilitation process have on
individual patient’s goals and priorities at discharge?
 To what extent do patients maintain coping, one
month after discharge?
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 What resource use and costs occur for patients and
their relatives, and for the rest of the health care
system?
 What is the relationship between the obtained
effects and costs?
Methods and design
The study is designed as a pragmatic clinical trial [9] of
a complex intervention with personalized outcomes [10].
It attempts to maximize external validity by incorpora-
ting important features of the rehabilitation intervention
in real-life settings and allowing individual participant-
selected treatment goals and personalized outcomes.
The study design (Figure 1) is a two-hospital controlled
trial of the rehabilitation intervention with randomization
to either early admission (‘intervention group’; admission
within two months after referral and clinical prescreening)
or usual admission (‘control group’; admission approxi-
mately eight months after referral to the hospital and clin-
ical prescreening). Any differences between these two
groups on observed measures between baseline and six-
month assessments will be considered as effects of the re-
habilitation program. As the control-group patients are
admitted to the hospitals after approximately eight
months from referral and prescreening, they also contrib-
ute with data to the effect of personalized rehabilitation.
To observe long-term effects, data collection will be
repeated after twelve months.
Participants
Study participants will be recruited among all patients
referred to the four-week individual rehabilitation pro-
gram during March 2012 to June 2013. Patients referred
for shorter rehabilitation programs or theme courses will
not be eligible for the study.
Participants must meet the following inclusion cri-
teria: aged between 18 and 65 years; diagnosis of
MS (relapsing remitting, primary or secondary pro-
gressive MS); Expanded Disability Status Scale (EDSS)
score ≤ 7.5 [11]; can use a personal computer or has a
support person/relative who can; ability to read and
understand sufficient Danish to understand instructions
both orally and in writing; completion of written
informed consent.
The following exclusion criteria will apply: less than
six months between diagnosis of MS and referral to the
program; disease relapse within three months of the
neurological appraisal; recipient of sclerosis-specific hos-
pital-based rehabilitation within the last six months; cog-
nition score (KFS) > 2 or cognitive limitations which
hinder completion of self-reported questionnaires and/
or informed consent; severe depression; severe heart or
lung disease; drug or alcohol abuse; any other illness that
can impede participation in the study. If participants de-
velop a disease that might impair their participation in
the study they will be excluded from the study at that
time.
Figure 1 Patient selection for a randomized study of a MS rehabilitation program.
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The final decision on participant inclusion or exclusion
will be based on the physician/neurologist assessment.
The study intervention
The purpose of the rehabilitation program is to provide
a personalized approach that allows the patient to de-
velop knowledge and understanding of the disease and
to maintain or develop the necessary resources and abi-
lities to manage their life situation.
The stages of the study intervention are described below
and include: initial screening; clinical examination prior to
inclusion; randomization; a preparation day; four-week
hospitalization; six and twelve months follow-up.
Initial study screening
Patients referred to the hospitals are routinely sent a
brief health screening questionnaire that upon return is
assessed by the admission nurse to exclude patients who
have a dependency level requiring intensive care and
thus lack the rehabilitation potential defined by the in-
clusion criteria (equivalent to a EDSS score >7.5). The
screening includes two basic models: factor evaluation
and prototype evaluation, and includes assessment of
physical and cognitive function/limitations (modified
Barthel-100 index) [12-14]. The screening can be con-
ducted as a home visit if necessary. Proposals for patient
exclusion from the study will be discussed with a neu-
rologist. The initial screening does not exclude wheel-
chair users or patients who need help from others to
complete the questionnaire.
Clinical examination prior to study inclusion
Patients who fulfill the initial screening criteria will re-
ceive by ordinary mail a study information pack inclu-
ding detailed information about the study and patients’
rights in a health science research project. Patients wil-
ling to participate in the study should respond within 10
days by phone or mail.
Potential participants will be invited to an ambulatory
consultation with a neurologist. The consultation will in-
clude standard neurological examination, screening for se-
vere depression [15] and a walking test. The neurologist
completes a screening form covering information about
the patient's previous and current medical treatment and
information relevant to the in- and exclusion criteria.
Patients will receive additional oral information about the
study and a final decision about participation is taken.
Patients who are not included in the study will continue
in the usual rehabilitation program. Information on fulfill-
ment of the in- and exclusion criteria, and stated reasons
for non-participation will be recorded. Patients who need
time to make a final decision whether to participate in the
study or not, should return a completed consent form
within two days of the clinical examination.
Randomization
Randomization will be performed by staff at the admit-
ting hospital using specialized computer software. To
ensure balance between different patient groups, the
randomization will be stratified according to gender, age
(four groups), MS type (three groups), duration of diag-
nosis (five groups), EDSS score (three groups), and
whether or not the patient is admitted to the hospital for
the first time (two groups).
Preparation day
The preparation day will take place seven days prior to
the scheduled hospitalization. The overall purpose of
the rehabilitation program will be explained and the in-
dividual areas for rehabilitation efforts will be defined in
a collaboration between the patient and an appointed
supervisor who serves as both the patient’s coach and as
an 'orchestra conductor' for the rehabilitation team du-
ring the entire hospitalization. Prior to this preparation
day, the patient will complete a FAMS form [16], a ques-
tionnaire on diet, smoking, alcohol and exercise, and in-
dicate which of five focus areas is most important for
him/her:
 Energy level, including fatigue, scheduling, breaks
and structure
 Cognitive function, including memory,
concentration and insight
 Physical function, including walking, balance,
endurance, strength and mobility
 Psychological well-being, including strengthening
coping mechanism, confidence, self-care, cognition
and adjustment processes
 Personal needs, including transferring, urination,
toilet visits, bathing and medication.
The patient will also complete Form one in MYCaW
[17,18]. The conversation follows clinical guidelines for
target setting content and includes COPM [19-22] as
identification and qualification of the decision basis for
the objective. The conversation leads to identification of
the primary goal within the five main areas (see above)
and specific subsidiary goals and described cf. Interna-
tional Classification of Functioning, Disability and Health
(ICF) classification of activity or participation level, sup-
plemented by specific milestones [23].
Four-week hospitalization
A hospitalization period of 20 days is organized as four
weeks of continuous hospitalization. A team of relevant
professionals is composed based on the assessment of
the patient's needs and may include neuropsychologist,
clinical psychologist, occupational therapist, physiothe-
rapist, nutritional therapist or dietitian, nurse, healthcare
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assistant, nursing assistant, social worker. The neurolo-
gist will carry out the primary standard neurological
examination and serve as consultant for the patient and
supervisor for the team. Symptomatic drug therapy is
organized or administered after the usual guidelines and
the neurologist’s judgment.
The patient’s supervisor is responsible for the content
of the patient's program and should oversee that it con-
tributes to the work of the team and patient, works to-
wards the agreed objectives and milestones and that the
necessary adjustments are made during hospitalization.
The supervisor and the patient continuously evaluate
the program, for example by weekly conversations, and
at discharge. According to patients’ wish, relatives and
other team members may participate in one or more of
the conversations.
During the rehabilitation period process data are col-
lected on selected specific rehabilitation interventions,
their nature, number, duration and medication.
Outcome measures
Patient outcome will be measured by a variety of stan-
dardized quality of life (QoL), mastery and individual
goal-related endpoints. A combination providing the basis
for analyzing the complexity of MS and outcomes of a
personalized rehabilitation.
Standard endpoints and associated measurement
instruments
 Disease-specific quality of life: Multiple Sclerosis
Impact Scale version 2 (MSIS-29) [24,25] and
Functional Assessment of Multiple Sclerosis (FAMS)
[16,26]
 Mastery: Health Education Impact Questionnaire
(heiQ) [27]
 Generic Quality of Life: EQ-5D [28-30] and 15D
[31]
 Expanded Disability Status Scale score (EDSS) [11]
 Fatigue: Modified Fatigue Impact Scale (MFIS) )
[32,33] (also used as individual endpoint)
 Sleep: Epworth Sleepness Scale (ESS) [34],
Pittsburghs Sleep Quality Index (PSQI) [35-38]
(also used as individual endpoint)
 Self-assessment of the severity of two main self-
selected problems for which the patient seeks help
and general feeling of well-being (MYCaW) [17,18]
 Resource consumption and costs for patients and
their relatives, and for the rest of health care service
Individual goal-related endpoints and associated
measurement instruments
After randomization, each participant will attend a pre-
paration day, when individual goals and endpoints for the
rehabilitation program will be determined according to
the following areas:
 Energy level: Modified Fatigue Impact Scale (MFIS)
[32], Epworth Sleepness Scale (ESS) [34], Pittsburghs
Sleep Quality Index (PSQI) [35-38]
 Cognitive function: Modified Fatigue Impact Scale
(MFIS) [32]
 Physical function: Six-minute walk test (6MWT)
[39-41], Multiple Sclerosis Walking Scale [42-45],
Dynamic Gait Index (DGI) [46,47], Five Times Sit-To-
Stand Test (5SST) [48,49], 9-Hole Peg Test (9-HPT)
[50-52] and Six Spot Step Test (SSST) [53,54]
 Psychological well-being and: Multiple Sclerosis
Self-Efficacy Scale (MSSE) [55-57] and Coping
Self-efficacy Scale (CSE) [58-60]
 Personal needs: Barthel-100 index [12-14,61]
These questionnaires and physical tests are selected to
capture changes in individual goals.
The Mastery (heiQ) and QoL (FAMS) are the only
tests to be performed also one month after discharge in
order to assess any changes in mastery and QoL shortly
after returning home.
The individually chosen tests will be supplemented by
Assessment of Motor and Process Skills (AMPS) [62,63]
that include measurements of efficiency, safety, autono-
my and effort in motor and process skills. This is rele-
vant for measurements of changes in all five focus areas.
Physical tests will be performed at the clinical exami-
nation prior to inclusion, at the preparation day, at dis-
charge and at 6 and 12 months follow-up. If the patient
has received an aid during the rehabilitation program,
the discharge tests will be performed both with and
without aids. For practical reasons and to avoid patient
burden, it is probably not possible to conduct all the
physical tests for a participant during one morning ses-
sion. Some tests may thus be delayed (after a rest or the
following day). Such an approach is not expected to in-
fluence the validity of the test results [64]. However as
patients are typically tested in the afternoon at inclusion,
they will also be retested in the afternoon at discharge to
avoid any effects of time differences.
Data collection
The data collection is planned as outlined in Table 1.
Measurement times for the early admission group in-
clude baseline (Time A1), preparation day (Time A2),
day of discharge (Time A3), one-month follow-up after
discharge (Time A4), six-month follow-up after baseline
(Time A5) and twelve-month follow-up after baseline
(Time A6).
Similarly, the six measurement times for the usual
admission group are baseline (Time B1), six-month
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follow-up after baseline (Time B2 - acts as the control
measurement – no intervention), the preparation day
(Time B3), day of discharge (Time B4), one-month fol-
low-up after discharge (Time B5) and twelve-month
follow-up after baseline (Time B6).
Collection of patient-reported outcomes will mainly be
based on online versions of the questionnaires, but ques-
tionnaires administered at the preparation day and at
discharge will be in paper versions (Table 2). Patients
who have completed the consent form will be assigned a
unique study identification number and a login code to
the web-based data collection system SurveyXact (www.
surveyXact.dk). This password provides access to the
questionnaire to be answered in accordance with the
measurement time.
Pilot study for data collection
In November 2011 a pilot study was conducted to test
and adjust the screening and randomization processes,
and to test the online survey facility. Data were collected
for 8 patients in accordance with the protocol for the
two groups. This pilot study identified a number of prac-
tical challenges that were addressed in the final study
protocol. The target group was expanded from only
patients who were referred for the first time to also
include patients who had previously been admitted to
the hospitals. The inclusion criteria were tightened to
require that participants should be able to respond to
the computerized questionnaires. A maximum age of
65 years and an additional exclusion criterion regarding





Baseline Time A1 Time B1
6 months after baseline Time B2
Preparation day Time A2 Time B3
Day of discharge Time A3 Time B4
1 months after discharge Time A4 Time B5
6 months after baseline Time A5
12 months after baseline Time A6 Time B6
Table 2 Questionnaires and assessments in the study
Instruments A1/B1 B2 A2/B3 A3/B4 A4/B5 A5 A6/B6
(baseline) (6 mths after
baseline)










Subsequent assessments x x x
Standard outcomes
MSIS-29 x x x x x
FAMS x x x x x x
heiQ x x x x x
EQ-VAS x x x x x
EQ-5D/15D x x x x
EDSS x x x x
MFIS x x x x
ESS/PSQ x x x x
MYCaW x x x x
Walking distance test x x x x
Goal-related outcomes
Energy-level x x x x
Cognitive function x x x x
Physical function x x x x
Psychological well-being x x x x
Personal needs x x x x
Motor and Process Skills x x x x
Services used during admission
Use of different services x
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other illnesses that could impede participation in the
study were introduced. In addition, the screening for de-
pression was changed to be part of the clinical assess-
ment rather than being based on self-assessment.
Register and economic data
In addition to data from questionnaires, data from rou-
tine administrative health registries will be obtained
from the Sclerosis Hospitals, the national patient registry
and the primary care registry (through the National
Board of Health’s research service) and the registry of
primary care prescription medicine. Data available in
these registries include records of actual resource con-
sumption (number of hospitalizations, outpatient visits
and consultations) and costs in terms of service fees, fees
paid to health care providers and pharmacy retail prices
(AUP). Data on vital status will be obtained from the na-
tional mortality registry. These data will be obtained for
the years 2010–14, i.e. for the two years prior to baseline
and up to the 12 months of follow-up.
Data analysis
Sample size calculation
Determination of the required sample size is based on
known data from the previous FAMS study [8,26]. The
FAMS total score ranges from 0-170 and the average
score at referral was 103 (SD 27). Assuming that a 5%
score change indicates a clinically significant change,
then the mean score should change to more than 108 i.e.
that a clinically significant change requires a 5-point
change.
To test a 5-point difference between two groups with
5% statistical significance (alpha) and 90% power (beta),
the calculated required number of participants in each
group is 613 people. With 80% power the required num-
ber of participants is reduced to 458.
If we want to test a 10-point difference, there needs to
be 154 people (assuming 90% power) or 115 people
(80% power).
The current study participants are expected to be a
more homogeneous group than in the previous study,
thus the variation in FAMS score is likely to be reduced.
If the standard deviation is assumed to be 20 (instead of
27), then 252 patients will be needed in each group to
identify a 5% difference with 80% power.
Taking into account correlation between repeated
measurements for the same individual and assuming
that the correlation between two subsequent measure-
ments is 0.8, a 5-point difference could be identified
with 160 participants (90% power) or 120 participants
(80% power) in each group.
Based on these assessments a reasonable sample size is
considered to be around 200 participants in each of the
two groups. The Sclerosis Hospitals expects to admit
1,200 people with multiple sclerosis in the period March
2012 through June 2013. An unknown number will be
either excluded from the study or will decline to partici-
pate in the study. If an insufficient number of patients
has been recruited at the end of the planned inclusion
period, a (short) extension of the inclusion period will be
possible.
Statistical analyses
Analysis will be both descriptive and comparative.
Descriptive analysis
Differences in personal and disease characteristics will
be compared between participants completing the study,
those who fulfill the inclusion criteria but decline par-
ticipation (primary drop-out), and those who participate
in parts of the study but for various reasons end partici-
pation (secondary drop-out). We will investigate for spe-
cific characteristics that distinguish drop-out individuals
from those who complete the study.
The included study population will be described and
the intervention and control groups will be compared
for eventual significant differences in personal and disease
characteristics. 'Intention to treat' analysis will be used for
comparing the efficacy of the two groups and longitudinal
random effects regression models (panel analysis) will be
applied.
Comparative analysis
The following comparative analysis will be conducted:
 Difference from Time A1 to Time A5 for
intervention group compared with the difference
from Time B1 to Time B2 for control group
(i.e. difference in outcomes for rehabilitation vs. no
rehabilitation at 6-month follow-up)
 Difference between Time A1 and Time B1
(i.e. difference between intervention and control
group at baseline)
 Difference between Time A1 and Times A5 and A6
(i.e. baseline vs. 6- and 12-month follow-up for
intervention group)
 Difference between Time B3 and Time B6 for control
group (i.e. admission vs. 12-month follow-up).
 Difference between A2 and A3 for intervention
group (pre- vs. post-hospital rehabilitation)
 Difference between B3 and B4 for control group
(pre- vs. post-hospital rehabilitation).
 Difference between Time A1 and Time A4 for
intervention group A (baseline vs. one month after
hospital rehabilitation)
 Difference between Time B3 and Time B5 for
control group (pre- vs. one month after hospital
rehabilitation)
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 Changes in Mastery (heiQ) over time: Times A1,
A4, A5 and A6 for intervention group compared
with Times B1, B2, B5 and B6 for control group
Subgroup analyses will be performed on the individual
focus areas, based on data from participants who have
completed the goal-related questionnaires.
Time scale
Patient recruitment will be ongoing and is expected to
be completed by mid-2013. Data collection is expected
to last a further twelve months until mid-2014. This
period will be followed by a one-year period of data ana-
lysis and manuscript preparation.
Blinding
It is not possible to blind participants in relation to
which group they are randomized to. Similarly, it is not
possible to blind the staff at the two hospitals regarding
participation in the study and randomization group.
Study participants will be admitted to the rehabilitation
program concurrently with non-participants. This means
that the intervention group and control group will be
treated alongside patients outside the study.
Ethics and permissions
Participation in the study will have no influence on the
offer of rehabilitation or its content. Patients who do not
wish to participate in the study will be treated as usual.
All study participants will regardless of the randomiza-
tion be offered rehabilitation.
The study is organized to meet the standards of the
Declaration of Helsinki and the study protocol has been
approved by the Research Ethics Committee of the
Zealand Region (ref.no. 1-01-83-0002-07). The Danish
Data Authority has granted permission to collect and store
the required project information (ref. no. 2011-41-6751).
The study is registered in the clinical trials database:
http://www.controlled-trials.com/ISRCTN05245917/.
The study has obtained permissions to use the stan-
dardized outcome instruments.
Discussion
This study is designed to investigate the effects of an in-
patient rehabilitation program offered to individuals with
multiple sclerosis. The results will contribute to further
development of MS rehabilitation services and to discus-
sions about the design and content of such service. The
results will also provide additional information to health
authorities responsible for providing and financing re-
habilitation services.
To our knowledge this study will be one of the first
randomized clinical trials to examine patient outcomes
from a personalized rehabilitation program for MS. A
wide variety of outcomes will be assessed immediately
after discharge as well as one, six and twelve months
after completion of the rehabilitation the program com-
pletion. A combination providing the basis for analyzing
the complexity of MS and outcomes of a personali-
zed rehabilitation. Cost-effectiveness will be assessed at
twelve months.
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